NurExone’s ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
TORONTO and HAIFA, Israel, Aug. 09, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB:NRXBF) (Germany: J90) (the “Company” or “NurExone”) is pleased to announce new data for its ExoPTEN nanodrug, marking a significant step towards commercial-grade manufacturing. Building on the announcement of a new Good Manufacturing Practice (“GMP”) compliant Contract Research Organization (“CRO”) partner, this study assessed the performance of ExoPTEN loaded with small interfering RNA (“siRNA”) produced by the new manufacturer (the “GMP Partner”).
Related news for (NRXBF)
- NurExone Biologic Inc. Announces First Quarter 2025 Financial Results and Provides Corporate Update
- NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update
- NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement
- NurExone Biologic Recognized as a 2025 TSX Venture 50(TM) Top Performing Stock
- NurExone Biologic to Present at MIXiii 2025; Professor Michael Belkin, Head of NurExone Ophthalmology Project, to Receive Lifetime Achievement Award